You complete a secure online intake covering your health history, current medications and goals. A licensed clinician reviews it and may follow up by message or video. If they determine treatment is appropriate for you, they issue a prescription that goes to a licensed pharmacy, which ships to your address in Mesquite. Check-ins continue online.
Not everyone qualifies. A clinician makes an independent judgment for each patient, and payment does not guarantee a prescription.
I-30 and I-635 intersect here, and US-80 runs east. Proximity to the interstates is the city's practical advantage and its traffic problem.
Online evaluation removes the trip from the equation. Your intake is completed from home, a licensed clinician reviews your history, and if treatment is appropriate a partner pharmacy ships to your Mesquite address. Nothing about the process requires you to be on the road.
Eastern Dallas County has thinner specialist coverage than the northern suburbs, and residents often route toward Dallas or Garland for care beyond primary.
Roughly 150,000 residents, with a majority-minority population and large Hispanic and Black communities. Telehealth does not add specialists to Dallas County, but it does mean your evaluation is not limited to whoever has an opening near you.
Distribution, retail, healthcare and manufacturing, with a substantial commuter population working in Dallas proper.
Because intake and follow-up are handled asynchronously rather than at a scheduled appointment time, an irregular or rotating schedule is not an obstacle. You complete your part when you can; a clinician reviews it afterward.
Mesquite lies east of Dallas along I-30 and I-635, an established suburb of mid-century neighborhoods extending toward Lake Ray Hubbard, with newer development pushing east into Kaufman County.
Mesquite has hosted a championship rodeo since the 1950s, an unusual civic identity for a city now firmly inside the Dallas metro.
Compounded semaglutide is prepared by a licensed pharmacy to fill an individual prescription and is not FDA-approved. The FDA does not review compounded preparations for safety, effectiveness or quality before they are marketed.
Semaglutide carries a boxed warning regarding thyroid C-cell tumors observed in rodents and is contraindicated in people with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. Common side effects are gastrointestinal — nausea, vomiting, diarrhea and constipation — and cluster after dose increases. Serious risks include pancreatitis, gallbladder disease and kidney injury from dehydration.